BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial ...

KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation ...

† Most-abundant zymogen granule proteins. ‡ Different isoforms present in zymogen granules. § Validated by morphological studies after identification by mass spectrometry. As the molecular ...

HAE is a rare genetic disorder estimated to affect about 1 in 10,000 to 1 in 50,000 people ... including Takeda's plasma kallikrein inhibitor Takhzyro (lanadelumab), which is dosed once every ...

With its cash reserves dwindling, the Belgian biotech desperately needed the phase 2b trial of its last remaining clinical asset THR-149, a plasma kallikrein ... received €1 million in ...

There are five broad categories consistently associated with salt sensitivity. These include demographic factors, racial and social factors, renal function factors, hormonal factors, and dietary ...

After hours: February 6 at 4:23:23 p.m. EST ...